<DOC>
	<DOCNO>NCT01205243</DOCNO>
	<brief_summary>An open label , multi-centre , non-interventional post-marketing surveillance ( PMS ) monitor safety efficacy ZIAGEN® administer Korean patient accord prescribe information .</brief_summary>
	<brief_title>ZIAGEN® Post-marketing Surveillance</brief_title>
	<detailed_description>This study collect clinical data , mainly focus safety , Korean population per requirement KFDA market authorization . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria>All subject must satisfy follow criterion . Subject treat combination antiretroviral agent treatment HIV infection . Subject consider follow post marketing surveillance protocol investigator . Subject treat ZIAGEN® accord prescribe information . As consider characteristic observational post marketing surveillance , exclusion criterion strict . All investigator prescribe ZIAGEN® accord prescribe information approve Korea . Subjects hypersensitivity ZIAGEN® ingredient Subjects moderate severe hepatic impairment Subject endstage renal disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Abacavir</keyword>
	<keyword>post-marketing surveillance</keyword>
</DOC>